Ozempic vs Mounjaro. Both Ozempic and Mounjaro are FDA-approved medications for the treatment of Type 2 Diabetes. Although these specific drugs have not been approved for weight loss, their sister drugs known as Wegovy and Zepbound with the same active ingredients are FDA-approved for weight loss. Here’s more about each medication.
Mounjaro is an FDA-approved prescription injectable medication designed to help adults with type 2 diabetes manage their blood sugar (glucose) levels. The main active ingredient is Tirzepatide.
Mounjaro helps:
Mounjaro is not FDA-approved for weight loss. However, a medication called Zepbound is FDA-approved for weight loss and they both contain the main active ingredient Tirzepatide.
According to Lilly Investors, Tirzepatide is a single molecule that activates the body's receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain that are important for appetite regulation. Tirzepatide has been shown to decrease food intake and modulate fat utilization.
A study shows that Tirzepatide resulted in sustained weight loss through the treatment period, averaging a 22.9% decrease in body weight with the 15 mg dose at the end of treatment.
Everyone’s experience with Mounjaro is different but the most common side effects include:
In studies, gastrointestinal (GI) side effects were more common in people taking Mounjaro than people taking a placebo, and people taking Mounjaro were more likely to stop treatment because of these side effects.
Ozempic® is a brand name for semaglutide (a type of GLP-1 agonist). It’s an injectable prescription medication that was FDA-approved for the treatment of adults with Type 2 diabetes. Its sister drug Wegovy (whose active ingredient is also Semaglutide) has been approved for weight loss. Since its release, research has shown that it significantly benefits not only weight loss but also reduces the risk of cardiac events, such as heart attacks and strokes.
Ozempic helps:
Ozempic (Semaglutide) is not FDA-approved for weight loss. Although, studies have shown that it does work for weight loss. A clinical trial shows that people lost on average 10-15lbs within 10 months of taking Semaglutide.
A clinical trial shows that Semaglutide lowers the risk of cardiovascular events in patients with diabetes. This study also shows that it reduces cardiovascular risk in individuals who do not have diabetes but are overweight or obese.
Mounjaro and Ozempic have similar side effects due to both having similar (not the same) mechanisms of action. The most common side effects of Ozempic include:
In a study published in JAMA Internal Medicine, researchers compared Ozempic and Mounjaro in real-world conditions. They found that people who took Mounjaro lost significantly more weight than those who took Ozempic. Moreover, the longer the patients took the drugs, the wider the gap.
Thanks for reading,
Your Admired Team
